Special Issue

SARS-CoV-2 Spike-Based Vaccines

Message from the Guest Editors

Structurally, SARS-CoV-2 is a nanostructural system consisting of nuclear material surrounded by coat proteins, including a spike (S) glycoprotein. The S protein is most crucial in ACE2 host-cell receptor binding, and hence, it is a main target of the immune system. Though the mortality caused by these □-CoV is substantial, a promising strategy and long-term solution to treat patients infected with the virus is still required. One effective method is to design innovative strategies to develop preventative vaccines considering proteins from the SARS-CoV-2 coronavirus itself. These self-derived vaccines can have several significant impacts on understanding □-CoV; they can induce immune responses, a critical component for vaccinology, and can trigger the production of an antibody repertoire. Despite the significant threat that COVID-19 variants pose to current vaccines, these mutations in the S protein can guide novel current/future key vaccines strategies. This Special Issue aims to gather research (reviews, short reports, hypotheses, research articles, etc.) that addresses all aspects of spike-based vaccine development and the implications of variants.

Guest Editors

Dr. Umesh Kalathiya
Dr. Monikaben Padariya
Dr. Peter Maple

Deadline for manuscript submissions

closed (31 August 2023)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/130740

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI